ProQR's Genetic Disorder Candidate Gets Orphan Drug Status
Zacks Investment Research | Sep 20, 2017 02:10AM ET
ProQR Therapeutics N.V. (NASDAQ:PRQR) announced that the FDA has granted orphan drug designation to its genetic disorder candidate, QR-313, for the treatment of dystrophic epidermolysis bullosa ("DEB").
ProQR’s share price has increased 2.1% so far this year, underperforming the industry ’s rise of 15.3% in the same time frame.
The company has already obtained orphan drug designation for its four other candidates, including its usher syndrome candidate, QRX-421, earlier this month.
We note that orphan drug designation is granted to drugs capable of treating diseases that affect less than 200,000 people in the United States. The status makes QR-313 eligible for seven years of marketing exclusivity in the country, following an approval for DEB. The designation also makes the company eligible for certain other benefits, including tax credits related to clinical trial expenses, exemption from the FDA-user fee and assistance from the FDA in clinical trial design.
QR-313 is a RNA-based therapy for treating DEB, which is caused by mutations in exon 73 of the COL7A1 gene. The mutation result in the loss of functional collagen type VII protein that makes the skin fragile.
ProQR is also engaged in developing RNA-based therapies for other genetic rare diseases including cystic fibrosis (QR-010) and Leber’s congenital amaurosis (QR-110).
In a restructuring move, the company spun off its central nervous system ("CNS") disorders focused company, Amylon Therapeutics, in late August. Amylon will develop RNA-based therapies for the treatment of a rare genetic disease, which leads to strokes in mid-adulthood. ProQR will own majority ownership stake in the newly formed, privately-held company.
Zacks Rank & Key Picks
ProQR has a Zacks Rank #2 (Buy). A few other stocks to consider in the biotech sector include Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and PDL BioPharma, Inc. (NASDAQ:PDLI) , While Alexion and Regeneron sport a Zacks Rank #1 (Strong Buy), PDL BioPharma carries a Zacks Rank #2. You can see .
Alexion Pharmaceuticals’ earnings per share estimates have moved up 5.3% to $5.60 for 2017 and 7.6% to $7.06 for 2018 over the last 60 days. The company delivered positive earnings surprises in the trailing four quarters, with an average beat of 11.12%. Share price of the company has increased 16.8% year to date.
Get The News You Want
Regeneron’s earnings per share estimates have increased 16.7% to $14.99 for 2017 and 8.6% to $16.64 for 2018 over the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 10.11%. Share price of the company has increased 17.5% year to date.
PDL BioPharma’s earnings per share estimates increased 263% to 69 cents for 2017 and 174% to 63 cents for 2018 over the last 60 days. The company has topped estimates in two of the trailing four quarters with an average of 33.79%. Shares are up 55.2% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.